← Leaderboards
Umesh C Sharma
State University Of New York At Buffalo
$2,741,350
Attributed
$2,741,350
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $476.5K · FY2017–25$500K$375K$250K$125K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,741,350 · 2
By mechanism
R01$1,754,500 · 1
K08$986,850 · 1
Top collaborators
No co-investigators on record.
Most similar at State University Of New York At Buffalo
Same institution · by research overlap
- Praveen Chandrasekharan$1,689,817
- Jurgen Bernd Bulitta$13,249,415
Others in their field
Other Emerging Leaders on “Myocardium”
- Wuqiang Zhu · Mayo Clinic Arizona$6,493,351
- Kim-Lien T Nguyen · Va Greater Los Angeles Healthcare System$5,861,342
- Yuichi Shimada · Columbia University Health Sciences$5,671,179
- Sangita Choudhury · Boston Children'S Hospital$4,321,874
- Jingli Cao · Weill Medical Coll Of Cornell Univ$4,242,863
- Stavros George Drakos · Va Salt Lake City Healthcare System$4,242,298
Research focus
MyocardiumMyocardial DysfunctionGalectin 3Knockout MiceMouse ModelMyocardialDesignGain Of FunctionHeart FailureIn VitroCoronary FibrosisMacrophageMediatingClinical ResearchCardiac MyocytesCyclin D1FibrosisFunctional DisorderAttenuatedHeartInflammatoryInflammationCardiacOverexpression
Grant awards (10)
Immunomodulation of Galectin-3 to Prevent Radiation-Induced Myocardial Fibrogenesis$398,750
R01 · FY2025 · HL · contact PI
Immunomodulation of Galectin-3 to Prevent Radiation-Induced Myocardial Fibrogenesis$398,750
R01 · FY2024 · HL · contact PI
Immunomodulation of Galectin-3 to Prevent Radiation-Induced Myocardial Fibrogenesis$398,750
R01 · FY2023 · HL · contact PI
Immunomodulation of Galectin-3 to Prevent Radiation-Induced Myocardial Fibrogenesis$279,125
R01 · FY2022 · HL · contact PI
Immunomodulation of Galectin-3 to Prevent Radiation-Induced Myocardial Fibrogenesis$279,125
R01 · FY2021 · HL · contact PI
Galectin-3-Mediated Post-Ischemic Myocardial Dysfunction and its Inhibition by a Novel Peptide N-Acetyl-Seryl-Aspartyl-Lysyl-Proline$197,370
K08 · FY2021 · HL · contact PI
Galectin-3-Mediated Post-Ischemic Myocardial Dysfunction and its Inhibition by a Novel Peptide N-Acetyl-Seryl-Aspartyl-Lysyl-Proline$197,370
K08 · FY2020 · HL · contact PI
Galectin-3-Mediated Post-Ischemic Myocardial Dysfunction and its Inhibition by a Novel Peptide N-Acetyl-Seryl-Aspartyl-Lysyl-Proline$197,370
K08 · FY2019 · HL · contact PI
Galectin-3-Mediated Post-Ischemic Myocardial Dysfunction and its Inhibition by a Novel Peptide N-Acetyl-Seryl-Aspartyl-Lysyl-Proline$197,370
K08 · FY2018 · HL · contact PI
Galectin-3-Mediated Post-Ischemic Myocardial Dysfunction and its Inhibition by a Novel Peptide N-Acetyl-Seryl-Aspartyl-Lysyl-Proline$197,370
K08 · FY2017 · HL · contact PI